✦ LIBER ✦

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

✍ Scribed by Seto, Takashi; Kiura, Katsuyuki; Nishio, Makoto; Nakagawa, Kazuhiko; Maemondo, Makoto; Inoue, Akira; Hida, Toyoaki; Yamamoto, Nobuyuki; Yoshioka, Hiroshige; Harada, Masao; Ohe, Yuichiro; Nogami, Naoyuki; Takeuchi, Kengo; Shimada, Tadashi; Tanaka, Tomohiro; Tamura, Tomohide

Book ID: 120271342
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 282 KB
Volume: 14
Category: Article
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(13)70142-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Retreatment of gefitinib in patients wit

Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: A single-arm, open-label, phase II study

✍ Oh, In-Jae; Ban, Hee-Jung; Kim, Kyu-Sik; Kim, Young-Chul 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 497 KB

Safety and activity of alectinib against

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study

✍ Gadgeel, Shirish M; Gandhi, Leena; Riely, Gregory J; Chiappori, Alberto A; West, 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 385 KB

9165 Motesanib or bevacizumab in combina

9165 Motesanib or bevacizumab in combination with paclitaxel and carboplatin in patients with advanced nonsquamous non-small cell lung cancer (NSCLC): interim results from a randomized, open-label, phase 2 study

✍ Blumenschein, G.; Schwartzberg, L.S.; Menon, H.; Mok, T.S.K.; Stephenson, J.J.; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Erlotinib versus chemotherapy as first-l

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

✍ Caicun Zhou; Yi-Long Wu; Gongyan Chen; Jifeng Feng; Xiao-Qing Liu; Changli Wang; 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 265 KB

9079 Pemetrexed in combination with cisp

9079 Pemetrexed in combination with cisplatin or carboplatin in the first line therapy of locally advanced or metastatic non-small cell lung cancer: a randomized, two-arm, parallel, open-label, multicentric phase 2 study

✍ Schuette, W.; Groeschel, A.; Sebastian, M.; Andreas, S.; Mueller, T.; Schneller, 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 70 KB

68O EFFICACY, SAFETY AND TOLERABILITY RE

68O EFFICACY, SAFETY AND TOLERABILITY RESULTS FROM A PHASE IV, OPEN-LABEL, SINGLE ARM STUDY OF 1ST-LINE GEFITINIB IN CAUCASIAN PATIENTS (PTS) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION-POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)

✍ Douillard, J.; Ostoros, G.; Cobo, M.; Ciuleanu, T.; McCormack, R.; Webster, A.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 45 KB